Abstract:The present work aims to prove the concept of tumor-targeted drug delivery mediated by platelets. Doxorubicin (DOX) attached to nanodiamonds (ND-DOX) was investigated as the model payload drug of platelets. In vitro experiments first showed that ND-DOX could be loaded in mouse platelets in a dose-dependent manner with a markedly higher efficiency and capacity than free DOX. ND-DOX-loaded platelets (Plt@ND-DOX) maintained viability and ND-DOX could be stably held in the platelets for at least 4 hr. Next, mouse Lewis lung cancer cells were found to activate Plt@ND-DOX and thereby stimulate cargo unloading of Plt@ND-DOX. The unloaded ND-DOX was taken up by co-cultured cancer cells which consequently exhibited loss of viability, proliferation suppression and apoptosis. In vivo, Plt@ND-DOX displayed significantly prolonged blood circulation time over ND-DOX and DOX in mice, and Lewis tumor grafts demonstrated infiltration, activation and cargo unloading of Plt@ND-DOX in the tumor tissue. Consequently, Plt@ND-DOX effectively reversed the growth of Lewis tumor grafts which exhibited significant inhibition of cell proliferation and apoptosis. Importantly, Plt@ND-DOX displayed a markedly higher therapeutic potency than free DOX but without the severe systemic toxicity associated with DOX. Our findings are concrete proof of platelets as efficient and efficacious carriers for tumor-targeted nano-drug delivery with the following features: 1) large loading capacity and high loading efficiency, 2) good tolerance of cargo drug, 3) stable cargo retention and no cargo unloading in the absence of stimulation, 4) prolonged blood circulation time, and 5) excellent tumor distribution and tumor-activated drug unloading leading to high therapeutic potency and few adverse effects. Platelets hold great potential as efficient and efficacious carriers for tumor-targeted nano-drug delivery.

Platelet-derived biomaterials for targeted drug delivery and tissue repair

Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond

Engineering Unactivated Platelets for Targeted Drug Delivery

From bench to bedside: Platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery

Recent advances in platelet engineering for anti-cancer therapies

Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting

Remote-Loaded Platelet Vesicles for Disease-Targeted Delivery of Therapeutics

Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects

Engineering Platelet-Mimicking Drug Delivery Vehicles

Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy

Nanoparticle biointerfacing by platelet membrane cloaking

Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery

Engineered Platelets: Advocates for Tumor Immunotherapy

Platelet‐inspired nanomedicine in hemostasis thrombosis and thromboinflammation

Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis

Unleashing the biomimetic targeting potential of platelet-derived nanocarriers on atherosclerosis

Platelet membrane-functionalized hollow mesoporous Prussian blue nanomedicine for comprehensive thrombolytic management by targeted enhanced fibrinolysis and ROS scavenging

Platelet Membrane Biomimetic Nanoparticles Combined With UTMD to Improve the Stability of Atherosclerotic Plaques

Platelets and Their Biomimetics for Regenerative Medicine and Cancer Therapies

Physical‐Matched Nanoplatelets Boost Heterogeneous Thrombi Targeting Through Self‐Adaptive Deformation for Thrombolysis and Endothelial Repairing

Drug Delivery: Activated Platelets‐Targeting Micelles with Controlled Drug Release for Effective Treatment of Primary and Metastatic Triple Negative Breast Cancer (Adv. Funct. Mater. 13/2019)